Superfoods Bio-Royal Jelly Eubias™, 50caps

Superfoods Bio-Royal Jelly Eubias™, 50caps

The first biological Royal Jelly in Capsules
Royal Jelly, one of the best foods, is now available in SuperfoodsTM. Knowing that in the market there are many companies that sell this food, we wanted to create a Royal Jelly that would be different as far as its quality, its quantity, and its price are concerned. So we created the first Biological Royal Jelly in Capsules. We felt it was necessary to offer you something pure and measurable. Now you will use the product in the right way since you will know how much of it you should take. You will also know that the product is biological. Moreover, we added a large amount of lyophilised royal jelly ( lyophilisation is a unique procedure that can remove moisture from the product without destroying its nutrients and at the same time, it gives the product the chance to keep its nutrients intact for up to 10 years), a quantity that corresponds to 26,25gr of fresh royal jelly.

So we have a large quantity of a product which is 100% biological. Its use is controlled and its retail price is 17,95 Euros. Last but not least, it does not need to be preserved in a fridge. It contains 50 capsules of 175mg.

It can be preserved outside the fridge when the temperature is up to 25o C. The dosage frequency is indicated on the package.

The effects of royal jelly on human beings
Royal Jelly is well-known in medical bibliography but almost unknown in the everyday medical practice. This study aimed at evaluating the effectiveness of Royal Jelly and its clinical and laboratory safety as far as the human body is concerned. According to the clinical and laboratory examination, the effectiveness of Royal Jelly fell into the categories of “deterioration”, “unchanged” and “improvement”.

The category “deterioration” includes cases where for various reasons during the treatment with Royal Jelly, the clinical and laboratory condition of the person being treated worsens. The category “unchanged” includes cases where the clinical and laboratory condition remains unchanged at the end of the treatment and the category “improvement” includes cases where the clinical and laboratory condition improves. The data are mentioned as average ( ) standard deviation. The results of the treatment were estimated with the t-test student. The value of p was considered important, as it was lower than 0,05.

The therapeutic activity field of Royal Jelly is wide and as a result, it has a positive effect on a large number of patients. We studied the effects of Royal Jelly on 137 patients and on 9 different illnesses (chart 1). Sixty-eight patients were men and sixty-nine patients were women. At the end of the treatment, according to the estimation, for different reasons 9 cases (6,6%) showed signs of deterioration, 35 cases (25,5%) fell into the “unchanged” category and 93 cases (67%) showed signs of improvement. The improvement is statistically important (t=5,68 and P<0,001).

In 23 patients with coronary heart disease who were treated with Royal Jelly, we noticed that the condition of 2 of them (8,7%) worsened, the condition of 6 of them (26,1%) remained unchanged and the condition of 15 of them (65,1%) improved. The improvement was statistically important (t=4,8 and P<0,001).

In 19 patients with hypercholesterolemia (13 men and 6 women aged 72,6 +/- 4,5 years) who were treated with Royal Jelly, we noticed that the condition of 5 of them (26,3%) remained unchanged and the condition of 14 of them (73,7%) improved. The improvement was statistically important (t=6,3 and P<0,0001).

In 18 patients with mild hypertension (8 men and 10 women aged 57+/- 3,9 years) who were treated with Royal Jelly, we noticed that the condition of 3 of them (16,7%) worsened, the condition of 4 of them (22,2%) remained unchanged and the condition of 11 of them (61,1%) improved because their levels of blood pressure were regulated. The improvement was statistically important (t=3,8 and P<0,001).

In 17 patients with chronic hepatitis (6 men and 11 women aged 52+/- 4,2 years) who were treated with Royal Jelly, we noticed that the condition of 6 of them (35,3%) remained unchanged and the condition of 11 of them (64,7%) improved. The improvement was statistically important (t=4,2 and P<0,001).

In 14 women with menopausal syndrome (aged 46,3+/- 2,7 years) who were treated with Royal Jelly, we noticed that the condition of 1 of them (7,2%) worsened, the condition of 2 of them (14,3%) remained unchanged and the condition of 11 of them improved significantly. The improvement was statistically important (t=6,7 and P<0,0001).

In 13 patients with diabetes type II (8 men and 5 women aged 61,3+/- 3,6 years) who were treated with Royal Jelly, we noticed that the condition of 1 of them (7,8%) worsened, the condition of 4 of them (30,8%) remained unchanged and the condition of 8 of them (61,4%) improved significantly. The improvement was statistically important (t=3,4 and P<0,001).

In 12 patients with bronchial asthma (8 men and 4 women aged 71,4+/- 6,2 years) who were treated with Royal Jelly, we noticed that the condition of 2 of them (16,7%) worsened, the condition of 3 of them (25%) remained unchanged and the condition of 7 of them (58,3%) improved. The improvement was statistically important (t=3,3 and P<0,001).